Vimpat and Azelastine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Vimpat (lacosamide) and Azelastine (azelastine hydrochloride). Common drug interactions include infection among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people have when they take Vimpat and Azelastine. It is created by eHealthMe based on reports of 50 people who take the same drugs from the FDA, and is updated regularly.

What is Vimpat?

Vimpat has active ingredients of lacosamide. It is often used in epilepsy. eHealthMe is studying from 20,831 Vimpat users. Check the latest studies of Vimpat.

What is Azelastine?

Azelastine has active ingredients of azelastine hydrochloride. It is often used in allergies. eHealthMe is studying from 17,400 Azelastine users. Check the latest studies of Azelastine.

On Jul, 17, 2026

50 people who take Vimpat and Azelastine together, and have interactions are studied.

Vimpat and Azelastine drug interactions.

What are the common drug interactions of Vimpat and Azelastine, by gender? *:

female:

Infection
Sinusitis (inflammation of sinus)
Upper respiratory tract infection
Injection site erythema (redness at injection site)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Urinary tract infection
Herpes zoster
Nausea (feeling of having an urge to vomit)
Asthma
Headache (pain in head)

male:

Chronic kidney disease
Ear deformity acquired
Affect lability (emotional incontinence)
Asthenia (weakness)
Bacterial toxaemia (blood contains bacterial toxins)
Balance disorder
Chest discomfort
Cough
Delirium (wild excitement)
Depression

What are the common drug interactions of Vimpat and Azelastine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Bacterial toxaemia (blood contains bacterial toxins)
Chest discomfort
Cough
Dyspnoea (difficult or laboured respiration)
Induration (thickening of tissue)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Influenza
Infusion site pruritus (severe itching at infusion site)
Infusion site urticaria (rash of round, red welts on the skin at infusion site)
Rash

30-39:

Pneumonia

40-49:

Affect lability (emotional incontinence)
Asthma
Depression
Dyspepsia (indigestion)
Fluid retention (an abnormal accumulation of fluid in the blood)
Increased appetite
Muscular weakness (muscle weakness)
Nausea (feeling of having an urge to vomit)
Surgery
Weight increased

50-59:

Chronic kidney disease
Nephrogenic anaemia (anaemia due to kidney disease)
Renal failure (kidney dysfunction)
Dyspnoea (difficult or laboured respiration)
Fibromyalgia (a long-term condition which causes pain all over the body)
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
Headache (pain in head)
Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
Nausea (feeling of having an urge to vomit)

60+:

Infection
Injection site erythema (redness at injection site)
Asthenia (weakness)
Balance disorder
Brain oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain)
Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Delirium (wild excitement)
Depression
Dysphagia (a condition in which swallowing is difficult or painful)
Failure to thrive (inadequate weight gain and physical growth in children)

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 12 people, 24.00%
Asthma: 6 people, 12.00%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 5 people, 10.00%
Immunodeficiency: 5 people, 10.00%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 4 people, 8.00%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 4 people, 8.00%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 4 people, 8.00%
Lung Disorder (lung disease): 3 people, 6.00%
Hereditary Angioedema (recurrent episodes of severe swelling): 3 people, 6.00%

* Approximation only. Some reports may have incomplete information.

Do you take Vimpat and Azelastine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously